Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Modest Step-ups for Biotech's Private Investors

This article was originally published in Start Up

Executive Summary

Those venture capitalists with investments in the seven biotech companies that went public this year actually have reason for some degree of satisfaction: on average, they made pretty good money.

You may also be interested in...



Biotech's 2004 IPOs: Better Rewards for VCs?

The biotech IPO window cracked open slightly last year for seven companies with manageable step-ups-but will the market be more receptive in 2004 to firms seeking bigger windfalls?

Sobering Results So Far for Biotech's Private Investors

If venture capitalists were hoping to see a big profit, not merely liquidity, from a biotech IPO window, they've been seriously disappointed. Average step-up multiples for the seven biotech companies that went public in 2003 are quite low, especially compared to the heyday of 2000.

Which Private Investors are Cashing Out?

Every venture capitalist is anxious to use the latest IPO window to get his companies liquid. But some firms are more successful than others. At the top of the list there were few surprises--JP Morgan Partners and Alta Partners, with six biotech IPOs each, and MPM Capital with five. But the next group down contained some newer names.

Topics

Related Companies

UsernamePublicRestriction

Register

SC090828

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel